The stock of Lineage Cell Therapeutics Inc. (AMEX:LCTX) decreased by -$0.06 on Wednesday to $1.40, down -4.10 percent. The last five days have seen an average of 461,512 shares of common stock traded. 10 times new highs were reached in the current year, with a gain of $0.2100. The average number of shares traded over the last 20 days was 464,128, while the average volume over the last 50 days totaled 912,589.
LCTX stock dropped -4.10% since last month. On 07/25/23, the company’s shares reached a one-month low of $1.3500. The stock touched a high of $1.60 on 01/18/23, after rallying from a low of $1.02 in 52 weeks. The price of LCTX stock has risen by 19.67% or $0.2100 this year, reaching a new high 10 times. Still, the stock price is down -12.22% from the 52-week high.
Valuation Metrics
Beta for the stock is 1.66. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 20.13, the price-to-book (PB) ratio of 3.41, and the price-to-cash flow ratio of 342.24.
Financial Health
For the three months ended June 29, Lineage Cell Therapeutics Inc.’s quick ratio was 2.90, while its current ratio was 2.90, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 94.30% percent. Based on annual data, it had gross profit of $13.97 million and revenue of $14.7 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. LCTX’s return on assets (ROA) during the last 12 months has been -20.90%. There was a -31.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -34.40%.
Earnings Surprise
According to Lineage Cell Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $31.36 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $2.39 million, while revenues fell by -119.25% to $1.92 million. It was predicted that Lineage Cell Therapeutics Inc.’s quarterly earnings would be -$0.03, but it ended up being -$0.04, beating the consensus by 25.00%. EBITDA was -$4.77 million for the quarter. At the end of Lineage Cell Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 40.43 million, while its total debt was $3.4 million. Equity owned by shareholders amounts to $174.99 million.
Technical Picture
Here’s a quick look at Lineage Cell Therapeutics Inc.’s (LCTX) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 43.97%, suggesting the stock is Neutral, with a 40.37% historical volatility rate.
The stochastic %K and %D were 30.72% and 37.56% respectively, while the average true range (ATR) was 0.0767. Based on the 14-day stochastic reading of 5.88%, the RSI (14) reading is 46.66%. On the 9-day MACD Oscillator, the stock is at 0.0011.
Analyst Ratings
In its analyst report released on November 02, 2022, Robert W. Baird began covering Lineage Cell Therapeutics Inc. (AMEX: LCTX). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Lineage Cell Therapeutics Inc. (LCTX) an Buy rating. LCTX is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 5 others recommend it as a buy.
What is LCTX’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $7.00, with a median target price of $5.50. In analyzing these forecasts, the average price target given by analysts for Lineage Cell Therapeutics Inc. (LCTX) is $5.50.
